Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Xuelan Zuo"'
Autor:
Jie Jin, Lei Zhang, Albert Qin, Daoxiang Wu, Zonghong Shao, Jie Bai, Suning Chen, Minghui Duan, Hu Zhou, Na Xu, Sujiang Zhang, Xuelan Zuo, Xin Du, Li Wang, Pei Li, Xuhan Zhang, Yaning Li, Jingjing Zhang, Wei Wang, Weihong Shen, Oleh Zagrijtschuk, Raymond Urbanski, Toshiaki Sato, Zhijian Xiao
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-5 (2023)
Abstract Ropeginterferon alfa-2b represents a new-generation pegylated interferon-based therapy and is administered every 2–4 weeks. It is approved for polycythemia vera (PV) treatment in the United States and Europe with a starting dose of 100 µg
Externí odkaz:
https://doaj.org/article/47da0a8a91504cafb29f590303295981
Publikováno v:
Cancer Control, Vol 30 (2023)
Introduction Classical Philadelphia-negative myeloproliferative neoplasm (MPN) includes Essential Thrombocythemia (ET), Polycythemia Vera (PV) and Primary Myelofibrosis (PMF). The JAK2V617F mutation is part of the major criteria for diagnosis of MPN.
Externí odkaz:
https://doaj.org/article/29b95ce43b4e45d786ffa0bf444fdc93
Autor:
Yuqin, Song, Yanyan, Liu, Zhi-Ming, Li, Lanfang, Li, Hang, Su, Zhengming, Jin, Xuelan, Zuo, Jianyuan, Wu, Hui, Zhou, Kunyan, Li, Chuan, He, Jianfeng, Zhou, Junyuan, Qi, Siguo, Hao, Zhen, Cai, Yijing, Li, Weiwei, Wang, Xiaojing, Zhang, Jianjun, Zou, Jun, Zhu
Publikováno v:
The Lancet Haematology. 9:e493-e503
Dysregulation of EZH2 has a crucial role in lymphomagenesis. We did a first-in-human study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of SHR2554, an oral EZH2 inhibitor, in patients with relapsed or re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24dd78665d8b79af0782953d4e4826fa
https://doi.org/10.1016/s2352-3026(22)00134-x
https://doi.org/10.1016/s2352-3026(22)00134-x
Autor:
null Sanyun Wu, null Ping Luo, null Tuerxunayi Rouzi, null Yalan Yu, null Bei Xiong, null Yingying Wang, null Xuelan Zuo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186b2173018fd475f5620ec6d75f6886
https://doi.org/10.1177/10732748231163648/v2/response1
https://doi.org/10.1177/10732748231163648/v2/response1
Publikováno v:
Annals of Hematology. 101:705-708
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1e4cf980c86b30853a634a4543db711
https://doi.org/10.1007/s00277-021-04561-5
https://doi.org/10.1007/s00277-021-04561-5
Autor:
Jie Jin, Lei Zhang, Zonghong Shao, Jie Bai, Suning Chen, Minghui Duan, Sujiang Zhang, Hu Zhou, Na Xu, Xin Du, Xuelan Zuo, Li Wang, Pei Li, Xuhan Zhang, Daoxiang Wu, Yaning Li, Jingjing Zhang, Wei Wang, Warren Shen, Oleh Zagrijtschuk, Raymond Urbanski, Toshiaki Sato, Albert Qin, Zhijian Xiao
Publikováno v:
Blood. 140:6858-6859
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41c8ba2ada12fd1e6437dc956dd350ce
https://doi.org/10.1182/blood-2022-165789
https://doi.org/10.1182/blood-2022-165789
Autor:
Kazuya Shimoda, Vikas Gupta, Carolyn Mead-Harvey, Virginia Abello, Ruben A. Mesa, Pablo J. Muxi, Jeanne Palmer, Krisstina Gowin, Grace Kam Li Shan, Heidi E. Kosiorek, Qian Jiang, Jean-Jacques Kiladjian, Blake T. Langlais, Xuelan Zuo, Kerry Taylor, Robyn M. Scherber, John Mascarenhas, Jennifer Huberty, Ann Brazeau, Naveen Pemmaraju, Alessandro M. Vannucchi, Michelle Woehrle, David Gómez-Almaguer, Norio Komatsu, Lesley A. Anderson, Michael J. Mauro, Guillermo Ruiz Arguelles, Amylou C. Dueck, Claire N. Harrison, Ryan Eckert, Holly L. Geyer
Publikováno v:
Blood
Background: The COVID pandemic has resulted in significant changes many aspects of daily living. To understand the impact that COVID-19 has had on the myeloproliferative neoplasm (MPN) patient population, we conducted an internet based survey. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efb7cee4272f4046ef2ccf85125c5427
https://doi.org/10.1182/blood-2020-138953
https://doi.org/10.1182/blood-2020-138953
Publikováno v:
Pathology & Oncology Research. 26:599-603
Hepatocellular carcinoma (HCC) is one of the most malignant cancer with high morbidity and mortality which lead to a serious burden to society. AFP (alpha-fetoprotein) is the most widely used serum biomarker to detect HCC worldwide. However, no AFP e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b317081ee3dc9245a537f3ccdc783645
https://doi.org/10.1007/s12253-019-00585-5
https://doi.org/10.1007/s12253-019-00585-5
Autor:
Yuqin Song, Yanyan Liu, Zhi-Ming Li, Lanfang Li, Hang Su, Zhengming Jin, Xuelan Zuo, Jianyuan Wu, Hui Zhou, Kunyan Li, Chuan He, Jianfeng Zhou, Junyuan Qi, Siguo Hao, Zhen Cai, Yijing Li, Weiwei Wang, Xiaojing Zhang, Jianjun Zou, Jun Zhu
Publikováno v:
Journal of Clinical Oncology. 40:7525-7525
7525 Background: Dysregulation of histone methyltransferase EZH2 plays critical roles in lymphomagenesis. Emerging evidence shows that EZH2 also contributes to tumor immune evasion. SHR2554 is an oral, small-molecule inhibitor exhibiting potent selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e5c92fcbba658bbab7ea012d20c6bca
https://doi.org/10.1200/jco.2022.40.16_suppl.7525
https://doi.org/10.1200/jco.2022.40.16_suppl.7525
Autor:
Yuqin Song, Hui Zhou, Huilai Zhang, Wei Liu, Yuerong Shuang, Keshu Zhou, Fangfang Lv, Hao Xu, Jianfeng Zhou, Wei Li, Huaqing Wang, Hongyu Zhang, Haiwen Huang, Qingyuan Zhang, Wei Xu, Zheng Ge, Ying Xiang, Shuye Wang, Da Gao, Shun’e Yang, Jinying Lin, Lin Wang, Liqun Zou, Meifang Zheng, Jing Liu, Zonghong Shao, Ying Pang, Ruixiang Xia, Zhendong Chen, Ming Hou, Hongxia Yao, Ru Feng, Zhen Cai, Mingzhi Zhang, Wenhua Ran, Lin Liu, Shan Zeng, Wei Yang, Peng Liu, Aibin Liang, Xuelan Zuo, Qingfeng Zou, Junxun Ma, Wei Sang, Ye Guo, Wei Zhang, Yongqing Cao, Yan Li, Jifeng Feng, Xin Du, Xiaohong Zhang, Hongguo Zhao, Jie Yu, Xing Sun, Jun Zhu, Lugui Qiu
Publikováno v:
Advances in therapy. 38(4)
Patients with diffuse large B-cell lymphoma (DLBCL) have limited access to rituximab. IBI301 is a recombinant chimeric murine/human anti-CD20 monoclonal antibody and is a candidate biosimilar to rituximab. This study aimed to assess the therapeutic e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf69a795ac38aba133514e6dcb5cb5fa
https://pubmed.ncbi.nlm.nih.gov/33751401
https://pubmed.ncbi.nlm.nih.gov/33751401